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Introduction
Membranous nephropathy (MN) is a glomerular disease 
histologically characterized by an uniform thickening of glomerular 
basement membranes (GBM) caused by subepithelial electron- dense 
deposits of immune complexes, in which the antibody is an IgG. In 
about 2/3 of cases the etiology of MN is unknown and the disease 
is called primary or idiopathic. In the remaining cases MN may be 
secondary to systemic or autoimmune diseases, malignancy, infections, 
toxic agents or drugs.
Much of the current information about the pathogenesis of MN 
comes from the active and passive experimental models of Heymann 
nephritis (HN). Many attempts have been made to identify the antigen 
involved in HN. Eventually it has been identified in a large glycoprotein 
of 515 kd, called megalin, an endocytic receptor expressed on the 
luminal surface of the renal proximal tubules [1-4]. In small animals, 
megalin is also present in clathrin coated pits located along the base 
of podocyte foot processes, where it complexes with a Receptor-
Associated Protein (RAP) that serves as a chaperon for megalin. In HN 
there are circulating antibodies directed against megalin that pass the 
GBM and bind to specific epitopes of megalin forming in situ immune 
complexes that attach to the GBM. The glomerular epithelial cells react 
by increasing the synthesis of megalin. Repeated cycles eventually lead 
to accumulation of immune complexes with consequent activation 
of reactive oxygen species, inflammation, and local activation of 
complement with formation of the cytolytic membrane-attack complex 
C5b-C9 [5]. 
However, the model of HN is not entirely applicable to iMN since 
megalin is not expressed on human podocytes. Thus, other antigens 
should trigger an antibody response and in situ deposition of immuno-
complexes may also result from circulating unknown antigens.
The seminal study of Becker et al. has identified the M-type 
phospholipase A2 receptor 1 (PLA2R1) as the major target antigen 
in iMN [6]. These investigators found that about 70% of patients 
with iMN had circulating autoantibodies directed against PLA2R1. 
This discovery soon confirmed by other investigators [7,8], led to 
hypothesize that iMN is an autoimmune disease in which circulating 
autoantibodies bind to PLA2R1 on podocytes leading to in situ 
formation of immune complexes, GBM inflammation, and massive 
proteinuria [9]. According to Salant [10], the development of idiopathic 
MN may be the result of three conditions: the presence of HLA-DQA1 
alleles that confer susceptibility to autoimmunity, polymorphism of 
PLA2R1 that creates a unique conformation that can represent a target 
for autoantibodies, and production of hypogalactosylated IgG4 anti-
PLA2R1 that activates the complement pathway. It is also possible that 
innate immunity is involved. Moreover, endogenous or external (i.e. 
virus or viral particles?) stimuli may increase the expression of PLA2R1 
or shed some “cryptic” epitopes of PLA2R1.
A similar model is proposed for lupus glomerulonephritis. 
Accumulating data indicate that antiviral immunity has relevance in 
the pathogenesis of lupus nephritis. This idea is based on the existence 
of genetic variants that promote the persistence of nuclear particles 
in the extracellular space or inside lysosomes. Such nuclear particles 
mimic viral particles and their RNA or DNA components activate 
viral nucleic acid recognition receptors in antigen-presenting cells. 
These autoadjuvant effects of endogenous nucleic acids promote an 
inappropriate immune interpretation of the nuclear particles during 
antigen presentation [11].
The aim of this review is to describe the clinical importance of 
measuring anti-PLA2R1 antibodies in patients with MN. An additional 
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scope is to extensively discuss the biotechnological methods available 
to measure circulating anti PLA2R1 antibodies. 
Risk HLA-DQA1 and PLA2R1 Alleles: a Trigger, a 
Bullet and a Target
The association of HLA with idiopathic membranous nephropathy 
has been shown serologically and through molecular typing [12] 
particularly with HLA-DR alleles in whites [13]. Since idiopathic 
membranous nephropathy is a rare disease, some authors further 
hypothesized that the disease would be reflected by alleles. 
A multicentric study [14] performed independent genome wide 
association studies of single-nucleotide polymorphisms (SNPs) 
in patients with idiopathic membranous nephropathy from three 
populations of white ancestry (75 French, 146 Dutch, and 335 British 
patients). The cases corroborated the associations with the HLA-DQA1 
and PLA2R1 alleles. The description of these genetic associations has 
important implications. First, data point to the possibility that sequence 
variations within HLA and PLA2R1 are responsible for the development 
of idiopathic membranous nephropathy in whites. Second, the study 
provides support for the finding, reported by Beck and colleagues, that 
PLA2R1 is associated with idiopathic membranous nephropathy [6] 
and it underlines the importance of PLA2R1 antibodies detection in 
diagnostic chart of iMN. It clearly appears that the risk of idiopathic 
membranous nephropathy is higher with the HLA-DQA1 allele than 
with the PLA2R1 allele, suggesting that the HLA-DQA1 allele might 
facilitate autoantibody development targeting not only PLA2R1 but 
also other antigens. Literature strongly suggest that an interaction 
between genetic variants of immune-system proteins and glomerular 
components form the basis for the development of idiopathic 
membranous nephropathy, establishing a trigger (the immune system), 
a bullet (PLA2R1 autoantibodies), and a target (glomerular antigen). 
However, the causative link between the presence of the HLA–DQA1 
risk allele and PLA2R1 autoantibodies remains unknown.
A report on a previous study, in which a traditional method 
was used (restriction-fragment–length polymorphism analysis), 
pointed out that HLA-DQA1 alleles could be involved in idiopathic 
membranous nephropathy [15]. HLA-DQA1 is part of a heterodimer 
consisting of an alpha chain (DQA) and a beta chain (DQB), both 
anchored in the membrane and forming the antigen-presenting 
groove. This heterodimer plays a central role in the immune system 
by presenting epitope peptides (9 to 15 amino acids in length) derived 
from extracellular antigenic proteins, which in idiopathic membranous 
nephropathy could, for example, be composed of extracellular 
PLA2R1 fragments [16]. Class II molecules are expressed in antigen-
presenting cells and both the alpha chain and the beta chain contain 
polymorphisms that determine peptide binding specificities. PLA2R1 
encodes a protein that probably exists in both a transmembrane form 
and a soluble form. The transmembrane receptor may increase in the 
clearance of phospholipase A2, thereby inhibiting its action. PLA2R1 is 
present in normal podocytes and in immune deposits in patients with 
idiopathic membranous nephropathy. Sequence variations in PLA2R1 
that are related to idiopathic membranous nephropathy could control 
the pattern of antigen-peptide processing through conformational 
change [17].
Detection of Anti-PLA2-R Antibodies 
Target antigen
Phospholipase A2 (PLA2) comprises a diverse family of 
lipolytic enzymes which hydrolyzes the sn-2 fatty acid ester bond of 
glycerophospholipids to produce free fatty acids and lysophspholipids 
[4]. Most of the biological activities of sPLA2s have been attributed to 
their enzymatic capacity to hydrolyze membrane phospholipids. 
In 2009, Beck et al. described the M-type phospholipase A2 
receptor as an autoantigen in MN based on immunoblot analysis and 
mass spectrometry [6].
PLA2R is a type I transmembrane glycoprotein with a molecular 
mass of 180 kDa and is composed of a large extracellular portion 
consisting of an N-terminal cysteine-rich region, a fibronectin- like 
type II domain, and a tandem repeat of eight carbohydrate- recognition 
domains (CRDs), as well as a short intracellular C-terminal region 
(Figure 1). Although PLA2R is expressed on alveolar type II epithelial 
cells and on neutrophils, data suggest that it is mainly restricted to 
kidney podocytes [5]. PLA2R has been found to promote senescence 
in human fibroblasts and is involved in both positive and negative 
regulation of secretory PLA2. Mammalian sPLA2 could attach to 
PLA2-R and induce pro-inflammatory signals by a receptor-mediated 
mechanism [5] (Table 1).
Antobody subclass
It is well know that iMN is an IgG4 dominant disease. Both Beck et 
al. and Qin et al. showed that antibodies against PLA2R were mainly of 
the IgG4 subclass, confirming the dominance of this immunoglobulin 
subclass [18,19]. Since IgG4 is not binding complement, this has 
sparked the debate on the pathogenic role of these antibodies. However, 
both Beck and Qin agree that other subclass specificities, particularly of 
the IgG1 and IgG3 subclass, can be found in most patients. The role 
of IgG4 is further questioned by the finding that IgG4 deposits in the 
biopsy do not always correlate with anti-PLA2R titre in serum [6,18]. 
Whereas the data of the initial publication of Beck et al. [6] which 
suggested the unique association of anti-PLA2R1 IgG4 and iMN, other 
studies were performed to better understand the role of IgG subclasses.
Hofstra et al. first evaluated IgG subclasses. IgG4 was the dominant 
subclass in the majority of patients. Titers of IgG4, but not IgG1 or 
IgG3, significantly correlated with the occurrence of spontaneous 
remission [8]. To describe the natural pattern of the IgG subclass 
response to PLA2R, Kanigicherla et al. analyzed a subset of patients 
whose serum and biopsy samples were taken within 6 months and who 
were untreated by immunosuppressive agents before sampling. IgG4 
and IgG2 subclasses, typically thought to be inefficient at complement 
fixation, were clearly dominant, constituting 50 and 37%, respectively, 
of the total subclass response [19].
Laboratory techniques
Direct immunofluorescence assay (DIA) was the first and pivotal 
technique to the detection of IgG4 deposit in glomeruli. PLA2R in 
immune deposits was initially assessed by confocal microscopy in 
paraffin blocks with affinity-purified specific anti- PLA2R antibodies 
(Figure 2, Panel A) [6]. The sensitivities of biopsy tests were 74% [6] 
but it has some practical limitations. It requires specialized equipment, 
including a confocal microscope, is not easy to automatize, is prone to 
human interpretation errors and delivers only semi-quantitative data, 
even when multiple incubations with different sample dilutions are 
performed.
In the light on these consideration Beck et al. employed a Western 
blot technique using glomerular extracts which were electrophoresed 
under nonreducing conditions [6]. Despite descriptions about an 
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improved variant of the method with a sensitivity of >90% [6], Western 
blotting analysis is difficult to use outside of an expert laboratory and 
the method is not suited for the evaluation of large sample numbers. 
These limitations led to the development of a recombinant cell-
based indirect immunofluorescence assay (RC-IFA) (Figure 2, Panel 
B) that uses the human cell line over-expressing the full-length 
human PLA2R1 as substrate [20] which is now commercially available 
(EUROIMMUN AG, Lubeck, Germany). For this assay slides are made 
that contain biochips containing HEK 293 cells transfected with cDNA 
coding for PLA2R and non-transfected cells as control. The bound 
antibodies are detected with FITC-labelled goat antihuman IgG. 
However, even though RC-IFA can be considered as the reference 
method for the determination of several autoantibodies against 
integral membrane proteins of the outer cell surface, like NMDAR in 
autoimmune encephalitis [21], aquaporin 4 in neuromyelitis optica 
[22], CUZD1/GP2 in Crohn’s disease [23], it has some practical 
limitations. It requires specialized equipment, including a fluorescence 
microscope, is not easy to automatize, is prone to human interpretation 
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Figure 1: M-Type Phospholipase A2 Receptor in Normal Kidney Tissue and Glomeruli: Domain structure of PLA2R, which is composed of an N-terminal cysteine rich 
domain (CysR), a fibronectin type II domain (FNII), eight CTLDs, a transmembrane domain (TM), and a short intracellular C-terminal tail (IC).
Author (year) Patients (n) PLA2R1+(n,%) Assay Remarks
Beck et al. (2009) [6] 37 26,7 WB
Hofstra et al. [8] 18 14,78 WB
Beck et al. (2011) [25] 35 25,71 WB
Debiec and Ronco [7] 42 24,57 IF
Hoxha et al. [20] 100 52,52 IF
Qin et al. [18] 60 49,82 WB Cross-sectional study; 66% positive if limiting analysis to patients with proteinuria >3.5 g/day
Hoxha et al. [20] 24 14,58 WB
Low titres of PLA2R present in 10/11 patients who were negative in standard assay Renal 
biopsies with mesangial or subendothelial deposits or glomerular infiltrating cells were 
excluded
Beck et al. (2011) [25] 14 12,86 WB Patient characteristics not provided
Hoxha et al. [20] 81 53,65 IF Prospective study
Schönermarck [9] 16 11,69 IF
Kanigicherla et al. [19] 40 29,73 ELISA
Hofstra et al. [8] 117 86,74 IF/ELISA Cross-sectional study; table reflects only patients with active disease
Hofstra et al. [8] 88 61,69 IF/IF Authors develop a standardized ELISA for the determination of autoantibodies against PLA2R1 that can be made widely available and used in a routine setting for clinical applications.
Salant [10] 200 196,98 ELISA Prospective study 
Oh et al. [26] 100 69,69 WB Authors develop a standardized ELISA
Behnert et al. [24] 165 85,52 IF/WB/ALBIA
Authors explored the relationship between anti-PLA2R and disease activity and clinical 
outcomes. 
An Anti-Phospholipase A2 Receptor Quantitative Immunoassay
aPLA2R +: anti-PLA2R antibodies detectable; WB: Western blot; IF: immunofluorescence test; ELISA: Enzyme-linked Immunosorbent Assay; ALBIA: Addressable Laser 
Bead Immunoassay
Table 1: Prevalence of anti-PLA2R in idiopathic membranous nephropathy.
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errors and delivers only semi-quantitative data, even when multiple 
incubations with different sample dilutions are performed.
More recently, an ELISA protocol was published that uses a 
recombinantly produced extracellular domain of PLA2R1 to form the 
solid-phase [8]. 
The authors measured PLA2R1 antibody titer and subclass in a well 
defined cohort of 117 Caucasian patients with idiopathic membranous 
nephropathy and nephrotic-range proteinuria [8]. In this cohort, 
PLA2R1 antibodies were positive in 74% and 72% of patients using 
IIFT and ELISA, respectively. Concordance between both tests was 
excellent.
Sera from healthy individuals were used to define the normal range. 
Using mean + 3 Standard Deviations (SD), they proposed a threshold 
above 40 U/ml as positive [8]. However the study did neither evaluate 
the robustness of the method nor its specificity on a large number of 
disease controls. 
More recently Behnert et al. develop a quantitative, high throughput 
capture immunoassay that has at least comparable sensitivity and 
specificity of the RC-IFA and avoids the subjective assessment of 
RC-IFA especially in the presence of other autoantibodies that may 
obscure a true positive result. They tested recombinant overexpressed 
PLA2R as a potential target on an addressable laser bead immunoassay 
(ALBIA) diagnostic platform [24]. This work indicates that in 
addition to conformational epitopes, human anti-PLA2R reactivity 
in a commercially available CBA and an addressable laser bead 
immunoassay is significantly absorbed by peptides representing 
epitopes of PLA2R [24].
Relationship between Serum anti-PLA2R and Disease 
Activity
A number of studies have been performed to better define the 
correlation between serum anti-PLA2R levels and iMN activity.
Beck et al. serially measured anti-PLA2R antibodies in 18 iMN 
patients in serum collected at baseline, during remission and at relapse 
of nephrotic proteinuria. Anti-PLA2R1 antibodies disappeared during 
remission and reappeared in all cases of relapse [6]. Hofstra et al. found 
that spontaneous remission occurred significantly less frequently in 
patients with high antibody titer [8]. In another study, a reduction 
of serum titer of anti-PLA2R1 antibodies preceded the decrease of 
proteinuria in iMN patients treated with Rituximab, suggesting that 
the antibody titer may predict patient’s outcome [25]. 
Qin et al. found a shorter time-remission in patients with lower 
titer of antibody and suggested that the anti-PLA2R1 titer might have 
a prognostic significance [18]. However, Oh et al. did not found that 
the antibody measurement at the onset of nephrotic syndrome could 
predict the clinical outcome of disease [26]. 
Taken together these results seem to indicate that changes of serum 
anti-PLA2R antibody titer may be an useful tool to assess the disease 
activity and might also predict the outcome. 
Future studies in larger patient cohorts are necessary to analyze 
if autoantibody reactivity to specific regions of the receptor is of 
prognostic relevance for the affected patients.
Diagnostic Values of Serum Antibodies versus Biopsy 
Hoxha et al. investigating in parallel serum and kidney biopsies 
of patients with iMN found a strong expression of PLA2R1 in the 
glomeruli of 61/88 patients, 60 of them showed also serum anti-
PLA2R1 positivity. The remaining 27 serum negative patients showed 
a faintly positivity for PLA2R1 staining at glomerular level, whereas 
in 15 patients a secondary cause of MN was found [20]. Svobodova 
et al. tested paraffin-embedded kidney biopsies of 84 patients with 
MN for the presence of PLA2R in glomerular immune deposits and 
measured circulating anti-PLA2R antibodies using the indirect 
immunofluorescence test. In 45 of 65 (69%) patients with iMN, PLA2R 
was detected in sub-epithelial deposits along GBM. Circulating anti-
PLA2R antibodies were detected in 20 of 31 (65%) sera from patients 
sampled during active disease. Six patients with active disease were 
negative for circulating anti-PLA2R antibodies despite PLA2R1 antigen 
positivity in the biopsies. Only 8 of 37 (22%) sera sampled at the time of 
remission were PLA2R positive while PLA2R1 antigen was found in 22 
of the 37 (59%) corresponding biopsies [27]. 
Thus, in most patients with iMN the serum anti-PLA2-R1 
antibodies positivity is of heavy diagnostic value whereas its negativity 
may require a histological confirmation or additional clinical research 
to exclude a secondary cause of MN. 
Literature review provided evidence that binding of autoantibodies 
to PLA2R domains is likely more complex than previously thought.
A B 
Figure 2: Immunofluorescence tests for anti-PLA2R antibodies: Panel A: direct immunofluorescence assay in the paraffin-embedded biopsy sample. Panel B: 
positive patient the antibodies bind to the PLA2R-positive transfected cells, leading to a positive indirect immunofluorescence staining.
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It is important to appreciate that even when proteins are ‘‘denatured’’ 
using various chemical modalities (i.e. mercaptoethanol, dithiothreitol, 
or SDS) that transfer from SDS polyacrylamide gels to solid phase 
matrices through an alcohol interphase can result in significant 
protein refolding. These findings supporting reports that human IMN 
autoantibody binding to PLA2R depends on conformational epitopes. 
It is well know that iMN is an IgG4 dominant disease, with IgG4 
being the dominant IgG subclass in renal biopsies of patients with 
iMN. Both Beck et al. and Qin et al. showed that antibodies against 
PLA2R were mainly of the IgG4 subclass, confirming the dominance 
of IgG4 [6,18].
However, the same authors agree that other subclass specificities, 
particularly of the IgG1 and IgG3 subclass, can be found in most patients 
[6,18]. The role of IgG4 is further questioned by the finding that IgG4 
deposits in the biopsy do not always correlate with anti-PLA2R titre in 
serum. Qu et al. did not observe IgG4 in 6/42 patients with iMN [28]. 
Hoxha reported three patients with anti-PLA2R in serum and PLA2R 
in the biopsy with negative IgG4 staining [20].
Conclusions 
Membranous nephropathy is an autoimmune disease usually 
associated with a nephrotic syndrome. Although the pathogenesis of 
iMN remains incompletely defined, a strong association with the HLA-
DQA1 allele has been found in patients with iMN. Ponticelli and Glassok 
in a more recent review hiphotized that endogenous or exogenous 
injuries, such viral attack, initiated tissue damage and caused structural 
alterations of PLA2R1. Several studies and animal models suggested 
that viruses and other infectious insults are implicated in the aetiology 
of many human autoimmune diseases [28]. In these studies, regardless 
of the initial antigenic the specificity of the immune response spreads to 
include self-epitopes other than that which initiated the inflammatory 
process. The resulting inflammation and tissue damage then primes a 
hierarchical cascade of auto reactive T-cell specificities, even allowing 
cryptic or sequestered epitopes to be processed and presented [28].
Apart from other clinical and histological parameters, the positivity 
of anti-PLA2R antibody may represent an useful and specific marker to 
discriminate between idiopathic and secondary MN. The accuracy of 
the test to identify iMN and to exclude secondary causes of MN awaits 
well-designed prospective studies, and it is expected that quantitation 
of the anti-PLA2R antibodies will be important for prediction of 
prognosis as well as guidance of therapy. However a few exceptions 
may occur. 
Although a relevant percentage of patients with iMN present 
high anti PLA2R1 titer, antibodies may be undetectable in few cases 
of histological confirmed iMN. This may be related to low sensitivity 
of the method employed, an early spontaneous remission of MN or 
finally a wrong diagnosis of iMN. Also when proteins are ‘‘denatured’’ 
using various chemical modalities can result in significant protein 
refolding. Behnert et al. also discovered that human autoantibodies to 
PLA2R appear to target multiple domains of the receptor, a finding that 
supports the phenomenon of inter-molecular epitope spreading of B 
cell responses [24]. 
It’s nevertheless true that the variability of ligand-autoantibodies 
interaction could be a critical step that affecting laboratory methods 
and could be explain some exceptions and incongruences presenting 
in the literature.
Finally, anti-PLA2R antibody serum measurement could be an 
alternative diagnostic tool to confirm the presence of iMN so allowing 
to avoid percutaneous renal biopsy in difficult cases. Although renal 
biopsy is extensively used for establishing the diagnosis, the prognosis, 
and the management of renal disease, it may be rarely responsible 
of minor or severe complications. Moreover there are some cases in 
whom percutaneous renal biopsy is controindicated such as bleeding 
diathesis, anatomic or functional unique kidney, small kidneys with 
cortical sclerosis or atrophy, uncooperative behaviour and pregnancy. 
In these conditions the serum anti PLA2R measurement has an 
irreplaceable role to assess the diagnosis of iMN.
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